Total trials
372
Active
128
Phase 3
8
Total enrollment
530,902
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ropivacain 5 mg/ml + Clonidine | — | — | — | — | 2 | ||
| Shingrix | — | — | — | — | — | 2 | |
| Collagenase Clostridium Histolyticum | — | — | — | — | — | 1 | |
| Indocyanine Green | — | — | — | — | — | 1 | |
| Adenosine | — | — | — | — | — | 1 | |
| vaccination with 2 doses of Shingrix vaccine | — | — | — | — | — | 1 | |
| Penicillin G_1200mg | — | — | — | — | — | 1 | |
| cloxacillin | — | — | — | — | — | 1 | |
| Afatinib/Dacomitinib | — | — | — | — | — | 1 | |
| Osimertinib | — | — | — | — | — | 1 | |
| L-menthol | — | — | — | — | — | 3 | |
| Aliskiren | — | — | — | — | — | 1 | |
| Enalapril | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Dapagliflozin | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| STEM-PD | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| TNF-inhibition | — | — | — | — | — | 1 |
Next readouts
- 2021-12-15
- 2024-09-01
- 2025-03-30
- 2025-12-31
- 2026-10-01
- 2026-12
- 2026-12-31
- 2027-01
- 2027-02
- 2027-03-01
Top conditions
- Breast Cancer9
- Osteoarthritis7
- Suicide, Attempted6
- Depression6
- Stroke6
- Carpal Tunnel Syndrome5
- Cancer5
- Hypertension5
Frequently asked questions about Region Skane
- How many clinical trials does Region Skane have on ClinicalTrials.gov?
- Region Skane is listed as the lead sponsor on 372 clinical trials in ClinicalTrials.gov, 128 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Region Skane's trials are in Phase 3?
- 8 of Region Skane's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does Region Skane focus on?
- Region Skane's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Osteoarthritis, Suicide, Attempted, Depression, Stroke.
- When are Region Skane's next clinical trial readouts?
- Region Skane has 10 upcoming primary-completion readouts tracked here; the soonest is “Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology”, expected around 2021-12-15.